id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-1060-0007,FDA,FDA-2019-E-1060,Patent Term Extension Letter from FDA CDER to U S Patent Trademark Office,Other,Letter(s),2020-07-27T04:00:00Z,2020,7,2020-07-28T04:00:00Z,,2020-07-28T13:44:11Z,,0,0,09000064847ad202
FDA-2019-E-1060-0006,FDA,FDA-2019-E-1060,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2020-06-22T04:00:00Z,2020,6,2020-06-22T04:00:00Z,,2020-06-22T18:07:34Z,,0,0,09000064846ff04a
FDA-2019-E-1060-0005,FDA,FDA-2019-E-1060,Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Determinations,2019-12-05T05:00:00Z,2019,12,2019-12-05T05:00:00Z,2020-06-03T03:59:59Z,2019-12-05T15:58:19Z,2019-26251,0,0,09000064841e85d7
FDA-2019-E-1060-0004,FDA,FDA-2019-E-1060,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T20:37:51Z,,0,0,0900006484116d47
FDA-2019-E-1060-0003,FDA,FDA-2019-E-1060,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-05-13T04:00:00Z,2019,5,2019-05-13T04:00:00Z,,2019-05-13T18:01:09Z,,0,0,0900006483c729a3
FDA-2019-E-1060-0001,FDA,FDA-2019-E-1060,Letter from U S Patent and Trademark Office,Other,Letter(s),2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T15:35:30Z,,0,0,0900006483ac34b2
FDA-2019-E-1060-0002,FDA,FDA-2019-E-1060,"Patent Extension Application for ANDEXXA Patent No. 8,889,129",Other,Application,2019-03-06T05:00:00Z,2019,3,2019-03-06T05:00:00Z,,2019-03-06T15:36:45Z,,0,0,0900006483ac36ac